2022-01-24T16:51:16-06:00 2021-03-31 111986323 MARCUM LLP 1899 L STREET NW SUITE 850 WASHINGTON DC 20036 990 2020-04-01 760514428 MELANOMA RESEARCH FOUNDATION MELA 8006731290 1420 K STREET NW 7TH FLOOR WASHINGTON DC 20005 KYLEIGH LIPIRA CEO 8006731290 2022-01-24 1 KYLEIGH LIPIRA 999009999 FRANK H SMITH P00639053 2022274000 2022-01-24 3 AAL1 IAL1 2020 2022-09-23 18:48:47Z KYLEIGH LIPIRA 1420 K STREET NW 7TH FLOOR WASHINGTON DC 20005 5128245 0 X WWW.MELANOMA.ORG X 1996 TX TO ERADICATE MELANOMA BY ACCELERATING MEDICAL RESEARCH WHILE EDUCATING TO AND ADVOCATING FOR THE MELANOMA COMMUNITY. 15 14 21 475 0 0 5777261 5117283 6830 0 14087 5925 -157942 5037 5640236 5128245 1316954 1273000 0 0 1553124 1500797 21542 0 325932 2311924 2034654 5203544 4808451 436692 319794 2657969 4048990 1740690 2234814 917279 1814176 THE MRF IS THE LARGEST INDEPENDENT ORGANIZATION DEVOTED TO MELANOMA. ITS MISSION IS TO ERADICATE MELANOMA BY ACCELERATING MEDICAL RESEARCH WHILE EDUCATING TO AND ADVOCATING FOR THE MELANOMA COMMUNITY. 0 0 1563863 THE MRF HAS A ROBUST EDUCATION PROGRAM AIMED AT EDUCATING PATIENTS AND PHYSICIANS ABOUT THE PREVENTION, DIAGNOSIS AND TREATMENT OF MELANOMA, AS WELL AS INCREASING OVERALL AWARENESS OF THE DISEASE. IN ADDITION, THE MRF MAINTAINS A LARGE PORTFOLIO OF FREE EDUCATIONAL MATERIALS THAT CAN BE USED AT FUNDRAISERS, DOCTORS' OFFICES, SCHOOLS AND HEALTH FAIRS.PART OF THE MRF'S EDUCATIONAL OFFERINGS ALSO INCLUDE PATIENT-FOCUSED EDUCATIONAL SYMPOSIA THROUGHOUT THE U.S., IMPACTING NEARLY 1,400 PEOPLE TOUCHED BY MELANOMA. THESE SYMPOSIA PROVIDE MELANOMA PATIENTS AND THE PEOPLE WHO SUPPORT THEM THE OPPORTUNITY TO LEARN FROM LEADING MELANOMA EXPERTS ON THE MOST CURRENT PREVENTION, DIAGNOSIS, TREATMENT AND RESEARCH INFORMATION. 1478127 1273000 THE MRF IS COMMITTED TO ADVANCING A BROAD SCIENTIFIC AGENDA ACROSS THE DISCIPLINES OF PREVENTION, DIAGNOSIS AND TREATMENT. ALTHOUGH THE MRF HAS ACHIEVED A NUMBER OF IMPORTANT SCIENTIFIC MILESTONES, MUCH MORE WORK REMAINS TO BE DONE. TO THIS END, THE MRF FUNDS A SPECTRUM OF RESEARCH GRANTS, SCIENTIFIC INITIATIVES, AND PROGRAMS FOR CUTANEOUS MELANOMA AND RARER MELANOMA SUBTYPES (E.G. OCULAR, PEDIATRIC, ACRAL AND MUCOSAL MELANOMA). ITS RESEARCH GRANT PROGRAM IS A COMPETITIVE, PEER-REVIEWED RESEARCH GRANT PROGRAM FOR INVESTIGATOR-INITIATED RESEARCH HAS BEEN IN EXISTENCE SINCE 1998. MRF-SUPPORTED RESEARCH IS OPEN TO MEDICAL STUDENTS THROUGH SENIOR INVESTIGATIVE TEAMS AND ENCOMPASS. 1016466 THE MRF'S ADVOCACY PROGRAM IS A PLATFORM FOR THOSE AFFECTED BY MELANOMA TO SHARE THEIR VOICE AND TRANSFORM MELANOMA CARE. PATIENTS, CAREGIVERS, SURVIVORS, HEALTHCARE PROFESSIONALS AND PARTNERS ALL PLAY A CRITICAL ROLE IN THE ADVANCEMENT OF BETTER OUTCOMES FOR THE OVER ONE MILLION AMERICANS LIVING WITH MELANOMA AND THEIR LOVED ONES. 4058456 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 21 0 1 21 1 0 0 0 0 0 0 0 0 0 0 0 0 X 15 14 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NY OH OK OR PA RI UT VA WA WI WV TN SC X KYLEIGH LIPIRA 8006731290 1420 K STREET NW 7TH FLOOR WASHINGTON DC 20005 KYLEIGH LIPIRA CEO 40.00 X 265847 0 8793 SUSAN M DORSEY CPA CONTROLLER 40.00 X 158535 0 3514 STEVE SILVERSTEIN CHAIR 2.00 X X 0 0 0 CHERYL STRATOS VICE CHAIR 2.00 X X 0 0 0 GEORGE P JAMESON TREASURER 2.00 X X 0 0 0 DOUGLAS BROADMAN SECRETARY 2.00 X X 0 0 0 STAN ADLER BOARD MEMBER 1.00 X 0 0 0 MICHAEL B ATKINS MD BOARD MEMBER 1.00 X 0 0 0 REBECCA K DREMAN BOARD MEMBER 1.00 X 0 0 0 JEFFREY HARRIS BOARD MEMBER 1.00 X 0 0 0 ANTHONY T HENDRICKSON BOARD MEMBER 1.00 X 0 0 0 ALISON MARTIN BOARD MEMBER 1.00 X 0 0 0 GLENN MERLINO BOARD MEMBER 1.00 X 0 0 0 WILLIAM G REILLY BOARD MEMBER 1.00 X 0 0 0 MARK WEINZIERL BOARD MEMBER 1.00 X 0 0 0 TOM WESTDYK BOARD MEMBER 1.00 X 0 0 0 JILL WROBEL BOARD MEMBER 1.00 X 0 0 0 424382 0 12307 2 0 1 0 JPA HEALTH COMM 1101 CONNECTICUT AVENUE NW SUITE WASHINGTON DC 20036 MARKETING AND ADVOCACY 221390 BLACKBAUD PO BOX 930256 ATLANTA GA 322930256 DONOR DATABASE & ACCOUNT. SUPPORT 194315 CLIFTONLARSONALLEN LLP PO BOX 829709 PHILADELPHIA PA 191829709 OUTSOURCED ACCOUNTING SERVICES 148974 3 5117283 5117283 5925 5925 OTHER 900099 5037 5037 5037 5128245 0 0 10962 X 1240000 1240000 33000 33000 408379 201415 83905 123059 856262 803132 22230 30900 21730 21579 79 72 120407 97015 9551 13841 94019 75063 7737 11219 1825 1825 198651 102099 96552 60145 60145 830538 725007 33336 72195 23841 19188 3699 954 181300 145916 28132 7252 308517 215248 67198 26071 204137 142423 44464 17250 13328 9199 3064 1065 74523 58312 780 15431 78613 63270 12198 3145 10202 7118 2222 862 MEMBERSHIP DUES 17677 14227 2743 707 REGISTRATION FEES 16456 13244 2553 659 STAFF DEVELOPMENT 8407 6629 787 991 RECOGNITION/AWARDS 6494 5227 1008 259 4808451 4058456 424063 325932 1373404 2471261 49385 41062 339577 636387 375613 343491 643130 428295 290232 214835 229758 341954 2657969 4048990 235124 271165 1212500 1106202 0 515505 293066 341942 1740690 2234814 X -449358 -1126822 1366637 2940998 917279 1814176 2657969 4048990 X 319794 64336 512767 X 0 1 X 1 0 X 5651905 5873258 5290886 5777261 5117283 27710593 5651905 5873258 5290886 5777261 5117283 27710593 3001364 24709229 29 56 123 6878 5925 13011 8152 2552 1789 913 5037 18443 27742047 786186 0.89070 0.94270 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER - 2016 AMOUNT: $ 8,152. 2017 AMOUNT: $ 2,552. 2018 AMOUNT: $ 1,789. 2019 AMOUNT: $ 913. 2020 AMOUNT: $ 5,037. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 0 0 0 0 0 1 60145 60145 0 PART II-B, LINE 1: A LOBBY FIRM IS RETAINED TO ASSIST WITH DEVELOPING, COORDINATING AND IMPLEMENTING AN ALL-ENCOMPASSING ADVOCACY PROGRAM WHICH INCLUDES BUT IS NOT LIMITED TO FEDERAL FUNDING FOR MELANOMA RESEARCH, ISSUES RELATED TO ADOLESCENTS AND YOUNG ADULTS, PEDIATRIC PATIENTS, RARE MELANOMA SUBTYPES, ACCESS TO CARE, PREVENTION AND SURVIVORSHIP. 170608 24380 146228 342370 325618 16752 130152 78297 51855 214835 DEFERRED RENT AND LEASE INCENTIVES 341942 341942 X 5974212 64336 781631 845967 5128245 0 5128245 5552065 781631 781631 4770434 38017 38017 4808451 PART X, LINE 2: THE FOUNDATION PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2021, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. PART XII, LINE 4B - OTHER ADJUSTMENTS: REFUND OF GRANT 38,017. 1 UNIVERSITY OF PITTSBURGH 500 ROSS STREET 154-0455 PITTSBURGH PA 15262 250965591 501(C)(3) 350000 TO SUPPORT MELANOMA CANCER RESEARCH BECKMAN RESEARCH INST OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 150000 TO SUPPORT MELANOMA CANCER RESEARCH MASSACHUSETTS GENERAL HOSPITAL PO BOX 3829 BOSTON MA 022413829 042697983 501(C)(3) 150000 TO SUPPORT MELANOMA CANCER RESEARCH THE ROCKEFELLER UNIVERSITY PO BOX 164 NEW YORK NY 10065 131624158 501(C)(3) 150000 TO SUPPORT MELANOMA CANCER RESEARCH THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 191044265 236434390 501(C)(3) 100000 TO SUPPORT MELANOMA CANCER RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER PO BOX 4266 HOUSTON TX 77210 746001118 501(C)(3) 100000 TO SUPPORT MELANOMA CANCER RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER PO BOX 2710 NEW YORK NY 100877106 131924236 501(C)(3) 100000 TO SUPPORT MELANOMA CANCER RESEARCH BRIGHAM & WOMEN'S HOSPITAL PO BOX 3149 BOSTON MA 022413149 042312909 501(C)(3) 65000 TO SUPPORT MELANOMA CANCER RESEARCH H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238636 501(C)(3) 50000 TO SUPPORT MELANOMA CANCER RESEARCH THOMAS JEFFERSON UNIVERSITY PO BOX 71331 PHILADELPHIA PA 191761331 231352294 501(C)(3) 10000 TO SUPPORT MELANOMA CANCER RESEARCH UCSF FOUNDATION 220 MONTGOMERY STREET 5TH FLOOR SAN FRANCISCO CA 94104 942829914 501(C)(3) 10000 TO SUPPORT MELANOMA CANCER RESEARCH 11 0 STUDENT MEDICAL AWARDS 11 33000 PART I, LINE 2: THE MRF'S SCIENTIFIC LEADERSHIP IS COMPRISED OF MULTIDISCIPLINARY EXPERTS IN BASIC AND TRANSLATIONAL RESEARCH, DERMATOLOGY, EPIDEMIOLOGY, GENOMICS, PATHOLOGY, SURGERY AND MEDICAL ONCOLOGY. MEMBERS OF ALL OUR ADVISORY/ STEERING COMMITTEES ARE VOLUNTEERS THAT ASSIST IN PROVIDING THE SCIENTIFIC DIRECTION OF THE MRF. X X 0 0 0 0 0 0 0 1 0 KYLEIGH LIPIRA CEO 246159 0 19688 0 0 0 6750 0 2043 0 274640 0 0 0 SUSAN M DORSEY CPA CONTROLLER 158535 0 0 0 0 0 2049 0 1465 0 162049 0 0 0 PART I, LINE 7 DURING THE YEAR ENDED MARCH 31, 2021, KYLEIGH LIPIRA, CEO, RECEIVED A BONUS PAYMENT IN THE AMOUNT OF $19,688 BASED ON HER PERFORMANCE. STAN ADLER ASSOCIATES STAN ADLER, BOARD MEMBER, IS ALSO THE CHAIR AND FOUNDER OF THE ASSOCIATES 72000 MRF PAID A RETAINER FEE TO THE ASSOCIATES FOR GRAPHIC DESIGN AND MARKETING SERVICES. 0 FORM 990, PART VI, SECTION B, LINE 11B THE CONTROLLER AND THE CHIEF EXECUTIVE OFFICER REVIEW THE FEDERAL FORM 990 PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. UPON SUBMISSION OF THE FINAL DRAFT, THE FORM 990 IS DISTRIBUTED TO THE BOARD OF DIRECTORS AND THE FINANCE COMMITTEE FOR THEIR REVIEW PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS DISTRIBUTED ANNUALLY TO ALL MEMBERS OF THE BOARD OF DIRECTORS, KEY PERSONNEL, AND COMMITTEE MEMBERS. EACH RECIPIENT OF THE POLICY RETURNS A SIGNED AND DATED RESPONSE FORM INDICATING THEY REVIEWED THE POLICY WHILE NOTING IF ANY CONFLICTS EXIST. FOLLOWING THE FULL DISCLOSURE OF A POSSIBLE CONFLICT OF INTEREST DURING THE YEAR, THE BOARD OF DIRECTORS WILL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS AND THE BOARD MEMBER WITH THE POSSIBLE CONFLICT WILL RECUSE HIMSELF OR HERSELF FROM THE DISCUSSION AND VOTE. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER IS DETERMINED IN THE EXECUTIVE SESSION OF A BOARD OF DIRECTORS MEETING AND IS BASED UPON COMPARABLE SALARY DATA. THE BOARD OF DIRECTORS CONVENES AN AD HOC COMPENSATION COMMITTEE THAT CONTRACTED WITH AN OUTSIDE EXPERT IN SALARY EVALUATION. THIS OUTSIDE GROUP LOOKS AT THE SALARIES OF ALL MRF MANAGEMENT AND COMPARES THOSE SALARIES WITH INDUSTRY STANDARDS, ADJUSTED FOR REGIONAL VARIATIONS. APPROPRIATE ADJUSTMENTS ARE MADE TO ENSURE THAT MRF SALARIES ARE IN KEEPING WITH BEST PRACTICES. THE LAST COMPENSATION REVIEW FOR THE CEO WAS CONDUCTED IN 2019. FORM 990, PART VI, SECTION C, LINE 19 MRF'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 645,198. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 67,086. TOTAL EXPENSES 712,284. PAYROLL FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 18,798. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 18,798. RECRUITING: PROGRAM SERVICE EXPENSES 11,459. MANAGEMENT AND GENERAL EXPENSES 1,361. FUNDRAISING EXPENSES 1,712. TOTAL EXPENSES 14,532. WEB DESIGN: PROGRAM SERVICE EXPENSES 68,350. MANAGEMENT AND GENERAL EXPENSES 13,177. FUNDRAISING EXPENSES 3,397. TOTAL EXPENSES 84,924. FORM 990, PART XI, LINE 9: GRANT REFUNDS 38,017. INCREASE OF NET ASSETS DUE TO MERGER 474,750.